Green Hygienics (GRYN) 10-Q 2 May 22 2022 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jan. 31, 2022	Mar. 15, 2022
Cover [Abstract]
Entity Registrant Name	GREEN HYGIENICS HOLDINGS INC.
Entity Central Index Key	0001443388
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--07-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Jan. 31, 2022
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2022
Entity Common Stock Shares Outstanding		44,482,138
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	000-54338
Entity Incorporation State Country Code	NV
Entity Tax Identification Number	26-2801338
Entity Interactive Data Current	Yes
Entity Address Address Line 1	13795 Blaisdell Place
Entity Address Address Line 2	Suite 202
Entity Address City Or Town	Poway
Entity Address State Or Province	CA
Entity Address Postal Zip Code	92064
City Area Code	1-855
Local Phone Number	802-0299

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jan. 31, 2022	Jul. 31, 2021
Current Assets
Cash	$ 1,334	$ 507,512
Inventory	267,901	0
Total Current Assets	269,235	507,512
Fixed Assets, Net (note 4)	5,334,663	5,522,326
Intangible Assets	35,000	25,000
Total Assets	5,638,898	6,054,838
Current Liabilities
Accounts Payable And Accrued Liabilities	692,097	749,592
Payroll Liabilities	444,234	304,383
Accounts Payable - Related Parties (note 7)	845,038	523,791
Accrued Interest Payable	70,921	58,953
Current Portion Of Long-term Debt (note 5)	3,622,602	3,557,594
Due To Related Parties (note 7)	3,472,971	3,128,463
Contingent Liabilities (note 11)	186,480	0
Total Current Liabilities	9,334,343	8,322,776
Long Term Liabilities
Notes Payable (less Current Portion) (note 5)	37,465	65,891
Mortgage Payable (note 5)	2,750,000	2,750,000
Second Mortgage Payable (note 5)	1,760,000	1,760,000
Total Long-term Liabilities	4,547,465	4,575,591
Total Current And Long-term Liabilities	13,881,808	12,898,367
Stockholder's Deficit
Common Stock, 375,000,000 Shares Authorized, $0.001 Par Value 44,482,138 And 44,126,138 Shares Issued And Outstanding Respectively	44,482	44,126
Stock Payable	100,000	812,000
Additional Paid-in Capital	52,065,550	51,186,075
Deficit	(60,452,942)	(58,885,730)
Total Stockholder's Deficit	(8,242,910)	(6,843,529)
Total Liabilities And Stockholder's Deficit	$ 5,638,898	$ 6,054,838

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jan. 31, 2022	Jul. 31, 2021
Condensed Consolidated Balance Sheets
Common Stock, Shares Authorized	375,000,000	375,000,000
Common Stock, Shares Par Value	$ 0.001	$ 0.001
Common Stock, Shares Issued	44,482,138	44,126,138
Common Stock, Shares Outstanding	44,482,138	44,126,138

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2022	Jan. 31, 2021
Revenue
Sales	$ 41,950	$ 0	$ 41,950	$ 0
Rental Income And Other	21,185	0	25,685	40,954
Total Revenue	63,135	0	67,635	40,954
Operating Expenses
General And Administrative	535,462	799,594	1,027,445	3,078,829
Contingent Liabilities Expense	186,480	0	186,480	0
Total Operating Expenses	721,942	799,594	1,213,925	3,078,829
Loss Before Other Income (expense)	(658,807)	(799,594)	(1,146,290)	(3,037,875)
Other Income (expense)
Interest Expense	(303,685)	(210,363)	(600,922)	(401,803)
Forgiveness Of Notes Payable	0	0	180,000	0
Total Other Income (expense)	(303,685)	(210,363)	(420,922)	(401,803)
Net Loss	$ (962,492)	$ (1,009,957)	$ (1,567,212)	$ (3,439,678)
Net Loss Per Share, Basic And Diluted	$ (0.02)	$ (0.02)	$ (0.04)	$ (0.08)
Weighted Average Shares Outstanding	44,482,138	42,145,268	44,482,138	41,551,096

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Deficit) (unaudited) - USD ($)	Total	Common Stock [Member]	Stock Payable [Member]	Additional Paid-In Capital	Retained Earnings (Accumulated Deficit)
Balance, Shares at Jul. 31, 2020		39,577,781
Balance, Amount at Jul. 31, 2020	$ (4,432,520)	$ 39,578	$ 192,000	$ 45,830,289	$ (50,494,387)
Common Stock Issued For Services, Shares		2,375,000
Common Stock Issued For Services, Amount	2,288,050	$ 2,375	92,000	2,377,675	0
Imputed Interest	114,685	$ 0	0	114,685	0
Common Stock Issued For Prepaid Services, Shares		150,857
Common Stock Issued For Prepaid Services, Amount	155,383	$ 151	0	155,232	0
Common Stock Issued For Fixed Assets, Shares		190,000
Common Stock Issued For Fixed Assets, Amount	188,700	$ 190	0	188,510	0
Net Loss	(3,439,678)	$ 0	0	0	(3,439,678)
Balance, Shares at Jan. 31, 2021		4,293,638
Balance, Amount at Jan. 31, 2021	(5,125,380)	$ 42,294	100,000	48,666,391	(53,934,065)
Balance, Shares at Jul. 31, 2021		44,126,138
Balance, Amount at Jul. 31, 2021	(6,843,529)	$ 44,126	812,000	51,186,075	(58,885,730)
Imputed Interest	80,275	0	0	80,275	0
Net Loss	(604,720)	$ 0	0	0	(604,720)
Common Stock Issued In Private Placement, Shares		356,000
Common Stock Issued In Private Placement, Amount	0	$ 356	(712,000)	711,644	0
Balance, Shares at Oct. 31, 2021		44,482,138
Balance, Amount at Oct. 31, 2021	(7,367,974)	$ 44,482	100,000	51,977,994	(59,490,450)
Balance, Shares at Jul. 31, 2021		44,126,138
Balance, Amount at Jul. 31, 2021	(6,843,529)	$ 44,126	812,000	51,186,075	(58,885,730)
Balance, Shares at Jan. 31, 2022		44,482,138
Balance, Amount at Jan. 31, 2022	(8,242,910)	$ 44,482	100,000	52,065,550	(60,452,942)
Balance, Shares at Oct. 31, 2021		44,482,138
Balance, Amount at Oct. 31, 2021	(7,367,974)	$ 44,482	100,000	51,977,994	(59,490,450)
Net Loss	(962,492)	0	0	0	(962,492)
Imputed Interest	87,556	$ 0	0	87,556	0
Balance, Shares at Jan. 31, 2022		44,482,138
Balance, Amount at Jan. 31, 2022	$ (8,242,910)	$ 44,482	$ 100,000	$ 52,065,550	$ (60,452,942)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)	6 Months Ended
	Jan. 31, 2022	Jan. 31, 2021
Operating Activities
Net Loss	$ (1,567,212)	$ (3,439,678)
Imputed Interest	167,831	114,985
Loss On Sale Of Assets	15,589	0
Depreciation Expense	122,099	63,465
Share Based Compensation	0	2,288,050
Amortization Of Discount On Note Payable	8,563	734
Non-cash Interest	0	715
Common Stock Issued For Vehicles	0	1,500
Changes In Operating Assets And Liabilities:
Other Current Assets	(10,000)	0
Inventory	(267,901)	(509,479)
Accrued Interest Payable	11,968	(90,040)
Accounts Payable, Accrued Payroll And Liabilities	82,356	(134,334)
Accounts Payable - Related Party	321,247	171,653
Deferred Revenue	0	(15,973)
Contingent Liability-	186,480	0
Net Cash Used In Operating Activities	(928,980)	(1,548,701)
Investing Activities
Cash Paid For Purchase Of Fixed Assets	(35,025)	(206,046)
Cash Received For Sale Of Fixed Assets	85,000
Net Cash Used In Investing Activities	49,975	(206,046)
Financing Activities
Payments On Convertible Note Payable	0	(171,213)
Proceeds From Notes Payable	0	1,502,326
Payments From Notes Payable	75,000	0
Payments To Related Parties	(77,913)	(435,229)
Payments On Notes Payable	(26,681)	(24,989)
Principal Payments On Agreements Payable	(20,000)	(17,978)
Advances From Related Parties	422,421	1,043,500
Net Cash Provided By Financing Activities	372,827	1,896,417
Decrease In Cash	(506,178)	141,670
Cash, Beginning Of Period	507,512	40,538
Cash, End Of Period	1,334	182,208
Supplemental Disclosures:
Interest Paid	588,954	322,909
Income Taxes Paid	0	0
Non-cash Transactions
Shares Issued For Stock Payable	712,000	92,000
Shares Issued For Vehicles	0	188,700
Shares Issued For Prepaid Expenses	0	155,383
Non-cash Repayment Of Related Party Payable	0	1,140,000
Reclass From Long Term Debt To Short Term	$ 0	$ 4,852

Nature of Operations and Contin

Nature of Operations and Continuance of Business	6 Months Ended
	Jan. 31, 2022
Nature of Operations and Continuance of Business
Nature Of Operations And Continuance Of Business	1. Nature of Operations and Continuance of Business Green Hygienics Holdings Inc. (the “Company”) was incorporated in the State of Nevada on June 12, 2008 as Silver Bay Resources, Inc. On June 30, 2010, the name was changed to Takedown Entertainment Inc. On July 24, 2012, the Company changed its name to Green Hygienics Holdings Inc. The Company is an innovative, full-scope, science-driven, premium hemp cultivation and branding enterprise focused on the cultivation and processing of industrial hemp for cannabidiol (“CBD”). The Hemp Farming Act of 2018 removed hemp from Schedule I controlled substances (defined as cannabis with less than 0.3% THC), making it an ordinary agricultural commodity. The Company’s business model includes generating revenues from the sale of hemp and premium-grade CBD products, creating trusted global consumer brands, developing valuable Intellectual Property, and growing the Company rapidly through strategic acquisitions. With direct regard to acquisitions, the Company acts as a business accelerator and a vertical integrator focusing to support rapid growth and development of companies with extraordinary potential. A novel strain of coronavirus (“COVID-19”) continues to spread and severely impact the economy of the United States and other countries around the world. Federal, state, and local governmental policies and initiatives designed to reduce the transmission of COVID-19 have resulted in, among other things, matters related to our ability to increase sales to existing and new customers, continue to perform on existing contracts, develop and deploy new technologies, expand our marketing capabilities and sales organization, the adoption of work-from-home or shelter-in-place policies. and to generate sufficient cash flow to operate our business and meet our obligations. The COVID-19 impact on the Company’s operations is consistent with the overall industry and publicly issued statements from competitors, partners, and vendors. More generally, the COVID-19 pandemic has and is expected to continue to adversely affect economies and financial markets globally, leading to a continued economic downturn, which is expected to decrease spending generally and could adversely affect demand for our products. It is not possible at this time to estimate the full impact that COVID-19 will have on our business, as the impact will depend on future developments which are highly uncertain and cannot be predicted. The extent to which our businesses may be affected by the COVID-19 pandemic will largely depend on both current and future developments, including its duration, spread, and treatment, including vaccines in various stages of development and federal approval, and related work and travel advisories and restrictions, all of which are highly uncertain and cannot be reasonably predicted at this time. Going Concern These condensed consolidated unaudited financial statements have been prepared on a going concern basis, which implies the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The Company has generated limited revenues since 2013. The continuation of the Company as a going concern is dependent upon the continued financial support from its shareholders, the ability of the Company to obtain necessary equity financing to continue operations, and the attainment of profitable operations. As of January 31, 2022, the Company has a working capital deficiency of $9,065,108 and has an accumulated deficit of $60,452,942. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Significant Accounting Policies

Significant Accounting Policies	6 Months Ended
	Jan. 31, 2022
Significant Accounting Policies
Significant Accounting Policies	2. Significant Accounting Policies (a) Basis of Presentation These financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States and are expressed in U.S. dollars. Certain amounts from the July 31, 2021 annual report may have been reclassified to conform to the presentation used in the current period. (b) Principles of Consolidation These financial statements include the accounts of the Company and its subsidiaries. Subsidiaries are all entities (including structured entities) which the Company controls. For accounting purposes, control is established by an investor when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. All inter-company balances and transactions are eliminated. (c) Use of Estimates The preparation of financial statements in accordance with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses in the reporting 21 allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. (d) Cash and Cash Equivalents The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance and trust funds to be cash equivalents. (e) Inventory Inventory is carried at the lower of cost or net realizable value, with the cost being determined on a first-in, first-out (FIFO) basis. The Company periodically reviews physical inventory and will record a reserve for excess and/or obsolete inventory if necessary. In July 2020, the Company planted its first large scale hemp crops for cultivation. The planting covers approximately 120 acres of land and three greenhouses. During the six months ended January 31, 2021, the Company purchased additional seeds and nutrients to plant in its greenhouses to be later transferred into the fields. The Company determined to recognize these costs as inventory as of January 31, 2021. These costs included approximately $61,000 for seeds and nutrients and $448,000 on labor to prepare the fields, plant seeds, and to begin harvesting. The Company anticipates harvesting and beginning to market and sell these crops during the fiscal year ending July 31, 2021. During the six months ended January 31,2022, the Company again recognized similar costs as inventory for the same period of 2021. These costs included approximately $267,901 in nutrients and labor to prepare the fields, plant seeds, and to begin harvesting. The Company anticipates harvesting these crops during the fiscal year ending July 31, 2022 (f) Impairment of Long-Lived Assets The Company evaluates the recoverability of its fixed assets and other assets in accordance with ASC 360-10-15, Impairment or Disposal of Long-Lived Assets (g) Related Party Transactions The Company follows ASC 850, Related Party Disclosures (h) Income Taxes The Company accounts for income taxes using the asset and liability method in accordance with ASC 740, “Income Taxes”. The asset and liability method provides that deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company records a valuation allowance to reduce deferred tax assets to the amount that is believed more likely than not to be realized. (i) Foreign Currency Translation The Company’s functional and reporting currency is the U.S. dollar. Transactions in foreign currencies are translated into the currency of measurement at the exchange rates in effect on the transaction date. Monetary balance sheet items expressed in foreign currencies are translated into U.S. dollars at the exchange rates in effect at the balance sheet date. The resulting exchange gains and losses are recognized in the statement of operations. (j) Financial Instruments and Fair Value Measures ASC 820, “Fair Value Measurements and Disclosures”, requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value: Level 1 Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets, quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets), or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. Level 3 Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The Company’s financial instruments consist principally of cash, accounts payable and accrued liabilities, loans payable, and amounts due to related parties. Pursuant to ASC 820, the fair value of cash is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. The recorded values of all other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations. (k) Stock-based Compensation The Company records stock-based compensation in accordance with ASC 718, “Compensation – Stock Compensation” and ASC 505, “Equity Based Payments to Non-Employees”, using the fair value method. All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. (l) Revenue and Deferred Revenue For the six months ended January 31,2022, the company recognized revenue from the sales of product for $49,150 and $ 21,185 in rental income from property. We recognized $40,954 in rental income for the six months ended January 31, 2021, from license fees pursuant to a license agreement for the right to use the premises at the Potrero Ranch Property for temporary storage of construction equipment. The tenant vacated the property in October 2020. The Company plans to continue to seek other additional similar license agreements or sub-leases of our properties. (m) Leases The Company evaluates lease assets and lease liabilities, (if any), pursuant to ASC 842, by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing transactions. As of the date of this report, the Company has no material transactions to report. (n) Loss Per Share The Company computes earnings (loss) per share in accordance with ASC 260, “Earnings per Share”. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement. Basic EPS is computed by dividing earnings (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. As of January 31, 2021, the Company does not have any potentially dilutive shares. (o) Comprehensive Loss ASC 220, “Comprehensive Income”, establishes standards for the reporting and display of comprehensive loss and its components in the financial statements. (p) Recent Accounting Pronouncements In July 2018, the FASB issued ASU No. 2018-10, Codification Improvements to Topic 842, Leases. The amendments in ASU 2018-10 provide additional clarification and implementation guidance on certain aspects of the previously issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”) and have the same effective and transition requirements as ASU 2016-02. Upon the effective date, ASU 2018-10 will supersede the current lease guidance in ASC Topic 840, Leases. Under the new guidance, lessees will be required to recognize for all leases, with the exception of short-term leases, a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis. Concurrently, lessees will be required to recognize a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. ASU 2018-10 is effective for private companies and emerging growth public companies for interim and annual reporting periods beginning after December 15, 2019, with early adoption permitted. The guidance is required to be applied using a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative periods presented in the financial statements. During the three and six months ended January 31, 2021, the Company assessed the impact this guidance had on its financial statements and concluded that at present ASU No. 2018-10 has no impact on its financial statements.

Fixed Assets

Fixed Assets	6 Months Ended
	Jan. 31, 2022
Fixed Assets
Fixed Assets	3. Fixed Assets Fixed assets are recorded at cost reduced by accumulated depreciation. Depreciation expense is recognized over the assets’ estimated useful lives using the straight-line method. Estimated useful lives are periodically reviewed and, when appropriate, changes are made prospectively. When certain events or changes in operating conditions occur, asset lives may be adjusted and an impairment assessment may be performed on the recoverability of the carrying amounts. Fixed assets consist of the following: Useful Life Balance at July 31, 2021 Additions (deletions) Accumulated Depreciation Balance at January 31, 2022 Production equipment 5 years $ 854,899 $ (102,177 ) $ (68,303 ) $ 684,419 Furniture and office equipment 5 years 4,859 - (817 ) 4,042 Buildings and improvements 15 years 450,206 - (16,366 ) 433,840 Land 4,212,362 - - 4,212,362 $ 5,522,326 $ (102,177 ) $ (85,486 ) $ 5,334,663 Fixed asset costs are being depreciated using the straight-line method based on the useful life of the asset. Depreciation expenses was $137,686 and $63,465 for the six months ended January 31, 2022, and 2021, respectively.

Loans Payable

Loans Payable	6 Months Ended
	Jan. 31, 2022
Loans Payable
Loans Payable	5. Loans Payable The Company has the following notes payable outstanding as of January 31, 2022, and July 31, 2021: January 31, 2022 July 31, 2021 Secured Promissory Note payable, interest at 15%, matures August 15, 2024. 1,760,000 1,760,000 Secured Promissory Note payable, interest at 6%, matures August 23, 2024 2,750,000 2,750,000 Promissory Note, interest at 5.66%, matures October 1, 2023 85,331 112,012 Paycheck Protection Program loan 444,850 444,850 Golden State note payable 55,000 - Secured Promissory Note payable, interest at 15%, matures June 15, 2022, net of discount 2,668,748 2,660,186 Promissory Note/ interest at 4.75, matures March 2,2022 406,138 406,137 Sub- total notes payable, net of discount 8,170,067 8,133,185 Less long-term portion 4,547,465 7,235,766 Current portion of notes payable $ 3,622,602 $ 897,409 On August 15, 2019, the Company entered into a Secured Promissory Note with a face value of $1,760,000, with a non-related party. The note requires monthly payments of interest only at the rate of 15% per annum. The note is secured by a second charge on the Deed of Trust on real property commonly known as Round Potrero Road, Potrero, California. The maturity date of the debt is August 15, 2024. On August 23, 2019, the Company entered into a Secured Promissory Note with a face value of $2,750,000, with a non-related party. The note requires monthly payments of interest only at the rate of 6% per annum. The note is secured by a Deed of Trust on real property commonly known as Round Potrero Road, Potrero, California. The maturity date of the debt is August 23, 2024. On September 12, 2019, the Company entered into a Promissory Note with a face value of $183,031 with a non-related party for the purchase of equipment. The note requires monthly payments of $4,290 including interest at the rate of 5.66% per annum for a period of 48 months commencing November 1, 2019. The loan is secured by a collateral charge on production equipment. Of the amount owed, $47,866 is included in current liabilities and $37,465 is included in long-term liabilities on the consolidated balance sheet resented herein. On April 30, 2020 the Company received loan proceeds in the amount of $444,850 under the Paycheck Protection Program (“PPP”). The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”), provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The loans and accrued interest are forgivable after eight weeks as long as the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains its payroll levels. The amount of loan forgiveness will be reduced if the borrower terminates employees or reduces salaries during the eight-week period. The unforgiven portion of the PPP loan is payable over two years at an interest rate of 1%, with a deferral of payments for the first six months. The Company believes it has used the proceeds for purposes consistent with the PPP, however, we cannot assure you that the Company will be eligible for forgiveness of the loan, in whole or in part. On December 15, 2020, the Company entered into a Secured Promissory Note with a face value of $2,668,748, with the same lender of the August 23, 2019, Secured Promissory Note. The principal balance of the note included an initial debt discount of $26,423, that will be amortized to interest expense over the term of the note. For the three and six months ended January 31, 2022, the Company recorded $100,078 and $200,156 of interest expense, respectfully. As of January 31, 2022, there remains $0 of unamortized debt discount. The note requires monthly payments of interest only at the rate of 15% per annum. The note is secured by a third Deed of Trust on real property commonly known as Round Potrero Road, Potrero, California. The maturity date of the debt is June 15, 2022. A portion of the face value of this note was used to repay $1,140,000 of related party amounts due (see Note 7).

Convertible Note Payable

Convertible Note Payable	6 Months Ended
	Jan. 31, 2022
Convertible Note Payable
Convertible Note Payable	6. Convertible Note Payable On December 19, 2019, the Company entered into an securities purchase agreement, which was amended on January 8, 2020 (collectively, the “SPA”) with Triton Funds, LP, an accredited investor (“Triton”), pursuant to which the Company issued and sold to Triton (i) a discounted convertible promissory note (the “Note”) in the aggregate principal amount of up to $750,000, due June 30, 2020, bearing interest at a rate of ten percent (10%) per annum and convertible into shares of the Company’s common stock at a conversion price of $2.50 per share and (ii) a common stock purchase warrant (the “Warrant”), exercisable for two (2) years, to purchase up to 250,000 shares of the Company’s common stock at an exercise price of $3.00 per share, subject to adjustment, for an aggregate purchase price of $600,000. If not exercised, the Warrant will expire at 5:00 pm EST on December 31, 2021. The Note can be prepaid at any time by paying 110% of the then outstanding principal, interest, default interest (if any), and any other amounts then due under the Note. The Note is initially convertible at a price per share equal to $2.50 (the “Fixed Conversion Price”); provided, however, that during the continuance of an event of default under the Note, the conversion price shall be equal to 75% of the lowest trading price of the Company’s common stock during the 30 trading days prior to conversion. On December 31, 2019, Triton paid an initial purchase price of $100,000 at the initial closing. The Company received net proceeds of $85,000 after paying fees of $15,000. On February 20, 2020, Triton paid the purchase price balance of $500,000. The original issue discount on the Note is a total of $150,000. On March 31, 2020, the Company and Triton entered into a Modification Agreement, pursuant to which (i) the Company paid $250,000 of the principal amount of the Note, bringing the principal balance of the Note on that date to $500,000, (ii) the maturity date of the Note was extended to August 20, 2020, (iii) the conversion price of the Note was established as 75% of the lowest trading price of our common stock during the 30 trading days prior to conversion, and (iv) the minimum volume weighted price requirement of the Note was deleted. As of July 31, 2020, the principal balance of the Note was $171,213. On August 19, 2020, the Company paid the remaining principal and accrued and unpaid interest in the aggregate of $200,000 and as of that date the note balance is $-0-.

Revenue and deferred revenue

Revenue and deferred revenue	6 Months Ended
	Jan. 31, 2022
Revenue and deferred revenue
Revenue And Deferred Revenue	4. Revenue and deferred revenue For the six months ended January 31,2022, the company recognized revenue from the sales of product for $49,150 and $ 21,185 in rental income from property. We recognized $40,954 in rental income for the six months ended January 31, 2021, from license fees pursuant to a license agreement for the right to use the premises at the Potrero Ranch Property for temporary storage of construction equipment. The tenant vacated the property in October 2020. The Company plans to continue to seek other additional similar license agreements or sub-leases of our properties.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jan. 31, 2022
Related Party Transactions
Related Party Transactions	7. Related Party Transactions Controlling Shareholder As of January 31, 2022, Alita Capital, Inc., together with its affiliates (collectively, “Alita”), is the controlling shareholder of the Company’s common stock, as Alita owns approximately 49.8% of our issued and outstanding common stock, accordingly, Alita has the ability to exercise significant control over our affairs, including the election of directors and most actions requiring the approval of shareholders, including the approval of any potential merger or sale of all or substantially all assets or segments of the Company, or the Company itself. Alita is controlled by Mr. Ron Loudoun, the Company’s Chief Executive Officer. Alita is subject to certain restrictions under federal securities laws on sales of its shares as an affiliate. Should Alita sell or otherwise dispose of all or a portion of its position in the Company, a change in ownership and control of the Company could occur. A change in ownership, as defined by Internal Revenue Code Section 382, could reduce the availability of the Company’s net operating losses (“NOLs”) for federal and state income tax purposes. Furthermore, a change of control could trigger the change of control provisions in a number of our material agreements. During the six months ended January 31, 2022, Alita made advances to the Company (including direct payments to vendors) and received reimbursements from the Company as follows: Balance July 31, 2021 $ 3,128,463 Advances 422,421 Reimbursements (77,913 ) Balance January 31, 2022 $ 3,472,971 The above balances as of January 31, 2021, and July 31, 2020, are presented in due to related parties on the condensed consolidated balance sheets presented herein. Imputed interest of $167,831 and $114,985 for the six months ended January 31, 2021, and 2020, respectively, has been recorded for the above related party debts with the offset to additional paid in capital. Management Fees and accounts payable – related parties For the six months ended January 31, 2022, the activity for expenses recognized expenses and payments to officers and former officers as follows: Balance at July 31, 2021 Additions Payments Balance at January 31, 2022 CEO, parent $ 180,000 $ 277,650 $ - $ 457,650 Chief Technology Officer (7,500 ) 7,500 5,000 (5,000 ) Chief Operating Officer 113,679 22,500 28,500 107,679 Chief Financial Officer - 22,500 8,250 14,250 Chief Communication Officer - 27,597 10,000 17,597 Chief Project Manager 40,468 22,750 7,500 55,718 Former CEO, subsidiary 67,500 - - 67,500 Former President, subsidiary 67,500 - - 67,500 Former Chief Agricultural Officer, subsidiary 27,144 - - 27,144 Former Director 35,000 - - 35,000 $ 523,791 $ 380,497 $ 59,250 $ 845,038 All of the above amounts are non-interest bearing, unsecured and due on demand, and are presented in accounts payable related parties on the condensed consolidated balance sheets presented herein. Other On September 21, 2020, the Company issued 50,000 shares of common stock in the aggregate to two relatives of our Chief Project Manager (the “CPM”) in exchange for production equipment, pursuant to a Stock Purchase Agreement dated September 3, 2020, with an effective date of January 31, 2020. The shares were valued at $51,500 based on OTC’s closing trade price on the date of the agreement (see Note 8).

Share Issuances

Share Issuances	6 Months Ended
	Jan. 31, 2022
Share Issuances
Share Issuances	8. Share Issuances On September 2, 2020, the Company issued 500,000 common shares to SRAX, Inc. (“SRAX”), in exchange for the right to use the SRAX Sequire platform, pursuant to a Platform Account Contract dated August 4, 2020. The shares were valued at $355,550 based on OTC’s closing trade price on the date of the agreement. On September 13, 2020, and concurrently with the execution of the Financing Agreement, the Company issued to GHS Investments, LLC, 150,857 restricted shares of its Common stock (the “Commitment Shares”) to offset transaction costs (see Note 9 (o)). The shares were valued at $155,383 based on OTC’s closing trade price on the date of the agreement and were recorded as a prepaid expense on the condensed consolidated balance sheets presented herein. The expense will be recognized upon the Company selling shares of common stock to GHS under the equity line (see Note 9 (o)). On September 21, 2020, the Company issued 250,000 shares of common stock to the CEO of the Company in exchange for consulting services, pursuant to his agreement dated August 1, 2019 (see Note 9 (b)). The shares were valued at $370,000 based on OTC’s closing trade price on the date of the agreement. On September 21, 2020, the Company issued 100,000 shares of common stock to the Company’s CPM in exchange for consulting services, pursuant to his consulting agreement dated August 1, 2019 (see Note 9 (c)). The shares were valued at $148,000 based on OTC’s closing trade price on the date of the agreement. On September 21, 2020, the Company issued 50,000 shares of common stock in the aggregate to two relatives of our CPM in exchange for production equipment, pursuant to a Stock Purchase Agreement dated September 3, 2020, with an effective date of January 31, 2020. The shares were valued at $51,500 based on OTC’s closing trade price on the date of the agreement. On September 21, 2020, the Company issued 100,000 shares of common stock to the Chief Science Officer of the Company pursuant to his employment agreement dated August 1, 2020 (see Note 9 (l)). The shares were valued at $87,250 based on OTC’s closing trade price on the date of the agreement. On September 21, 2020, the Company issued 25,000 common shares to the Assistant Agricultural Operations Manager of the Company in exchange for consulting services, pursuant to her consulting agreement dated August 1, 2019 (see Note 9 (e)). The shares were valued at $37,000 based on OTC’s closing trade price on the date of the agreement. On September 21, 2020, the Company issued 200,000 shares of common stock pursuant to a consulting agreement dated July 1, 2020. The value of the shares of $92,000 was recorded against stock payable. On September 21, 2020 and under the terms of the Placement Agreement dated September 18, 2020, with Boustead Securities LLC (“BSL”), the Company issued to BSL an advisory fee of two hundred fifty thousand (250,000) shares of common stock (see Note 9 (p)). The shares were valued at $187,500 based on OTC’s closing trade price on the date of the agreement. On September 21, 2020, the Company issued 50,000 shares to the Company’s CFO, pursuant to his consulting agreement dated February 13, 2020 (see Note 9 (i)). The shares were valued at $60,750 based on OTC’s closing trade price on the date of the agreement. On September 21, 2020, the Company issued 50,000 shares of common stock to a consultant for advice on real estate acquisitions, pursuant to his consulting agreement (see Note 9 (n)). The shares were valued at $58,500 based on OTC’s closing trade price on the date of the agreement. On September 21, 2020, the Company issued 125,000 shares of common stock to a consultant for advisory services to the Board of Directors of the Company, pursuant to his consulting agreement (see Note 9 (j)). The shares were valued at $113,750 based on OTC’s closing trade price on the date of the agreement. On September 21, 2020, the Company issued 125,000 shares of common stock to a consultant for advisory services to the Board of Directors of the Company, pursuant to his consulting agreement (see Note 9 (k)). The shares were valued at $113,750 based on OTC’s closing trade price on the date of the agreement. On September 21, 2020, the Company issued 100,000 shares of common stock to a consultant for services, pursuant to his agreement dated February 1, 2020 (see Note 9 (h)). The shares were valued at $187,000 based on OTC’s closing trade price on the date of the agreement. On September 21, 2020, the Company issued 125,000 shares of common stock to a shareholder for advisory services to the Company, pursuant to his consulting agreement August 1, 2019 (see Note 9 (d)). The shares were valued at $185,000 based on OTC’s closing trade price on the date of the agreement. On September 29, 2020, the Company issued 140,000 shares of common stock to a non-related third party for the purchase of farm vehicles, pursuant to a Stock Purchase Agreement dated July 27, 2020, and effective June 1, 2020. The shares were valued at $137,200 based on OTC’s closing trade price on the effective date of the agreement. On November 15, 2020, the Company issued 100,000 shares of restricted common stock to a consultant, pursuant to a consulting agreement dated November 15, 2019, for services performed as COO of the Company (see Note 9 (g)). The shares were valued at $200,000 based on OTC’s closing trade price on the effective date of the agreement. On November 15,2020, the Company issued 125,000 shares of restricted common stock to a consultant, pursuant to a consulting agreement dated August 18, 2020 (see Note 9 (m)). The shares were valued at $75,000 based on OTC’s closing trade price on the issuance date, pursuant to the agreement. On December 1, 2020, the Company issued 50,000 shares of restricted common stock to a consultant, pursuant to a consulting agreement dated December 1, 2020, for services performed as Corporate Communications Officer of the Company (see Note 9 (q)). The shares were valued at $34,000 based on OTC’s closing trade price on the effective date of the agreement. On January 15, 2021, the Company issued 100,000 shares of restricted common stock to a consultant, pursuant to a consulting agreement dated January 15, 2021, for services performed (see Note 9 (r)). The shares were valued at $75,000 based on OTC’s closing trade price on the effective date of the agreement.

Commitments Contingencies

Commitments Contingencies	6 Months Ended
	Jan. 31, 2022
Commitments Contingencies
Commitments/contingencies	9. Commitments/Contingencies (a) On September 1, 2018, the Company entered into a consulting agreement with the CTO, Jeff Palumbo, whereby the Company agreed to pay a consulting fee of $2,500 per month for a period of two years commencing August 1, 2018. The agreement can be extended to four years upon mutual agreement. Upon completion of a minimum $1,000,000 financing, the Company will increase this payment to $5,000 per month. Upon completion of a minimum $5,000,000 financing or profitable operations, the Company will increase this payment to an amount mutually agreed upon that reflects the market rate for services provided by the CTO. (b) On August 1, 2019, the Company entered into a consulting agreement with the CEO of the Company, Ron Loudoun, whereby the Company agreed to pay a consulting fee of $7,500 per month for a period of three years and pursuant to which, the Company issued the CEO 250,000 shares of common stock of the Company. The Company recorded expenses of $22,500 and 45,000 for the three and six months ended January 31, 2021 and 2020, respectively. Additionally, the Company agreed to issue an additional 250,000 shares of common stock per year for the remaining two years of the agreement. Pursuant to the agreement, during the six months ended January 31, 2021, the Company issued 250,000 shares of restricted common stock. (c) On August 1, 2019, the Company entered into a consulting agreement with the Chief Project Manager, Greg Stinson, whereby the Company agreed to pay a signing bonus of $15,000 and a consulting fee of $7,500 per month for a period of five years. Pursuant to the agreement, the Company also agreed to annually issue to the Consultant 200,000 shares of common stock of the Company. Pursuant to the agreement, during the six months ended January 31, 2021, the Company issued 100,000 shares of restricted common stock. (d) On August 1, 2019, the Company entered into a consulting agreement with a shareholder. Pursuant to the agreement, the consultant will provide general advisory services, strategic planning advice and support. The Company agreed to issue to the consultant 125,000 shares of restricted common stock of the Company on the one- year anniversary of the agreement. The shares were issued September 21, 2020. (e) On August 1, 2019, the Company entered into a consulting agreement with the Assistant Agricultural Operations Manager, Carol Snyder, whereby the Company agreed to pay a signing bonus of $4,000 and a consulting fee of $2,000 per month for a period of year. At the end of the six-month period, the Company may evaluate the performance with regards to an extension of the agreement. Pursuant to the agreement, the Company also issued the Consultant 25,000 shares of common stock of the Company. Pursuant to the agreement, during the six months ended January 31, 2021, the Company issued 25,000 shares of restricted common stock. (f) On November 15, 2019, the Company agreed to issue 100,000 common shares to a former Independent Director of the Company, William Creekmur, in exchange for consulting services. The shares were valued based on OTC’s closing trade price on the date of the agreement. The Company issued 50,000 of the shares on April 20, 2020. The remaining 50,000 shares valued at $100,000 have not been issued and are included in Stock payable as of January 31, 2021, and July 31, 2020. (g) On November 15, 2019, the Company entered into a consulting agreement with Kyle MacKinnon. Pursuant to the agreement, the consultant is to fulfill the role of Chief Operating Officer (the “COO”) of the Company. The Company agreed to compensate the consultant $7,500 per month and issue 200,000 shares of restricted common stock annually. Each year, the first 100,000 shares are to be issued on the effective date and subsequent anniversary dates and an additional 100,000 shares are to be issued six (6) months thereafter. On November 15, 2020, the Company issued 100,000 shares of restricted common stock. (h) On February 1, 2020, the Company entered onto a consulting agreement with David Racz as an advisor to the Board of Directors of the Company. Pursuant to the agreement, the consultant is to provide among other matters, strategic planning and general advisory services. The Consultant is to be issued 100,000 shares of restricted common stock, of which 50,000 were due on the effective date. On September 21, 2020, the Company issued 100,000 shares of restricted common stock. (i) On February 13, 2020, the Company entered into a six-month consulting agreement with the CFO of the Company, Todd Mueller, whereby the Company agreed to pay a consulting fee of 100,000 shares, 50,000 shares would be delivered upon the execution of the agreement (certificated on July 14, 2020) and 50,000 delivered in six months based on the continuation of the agreement. Following the initial term, the Company and the consultant may extend the term for up to 5 years on similar terms and conditions by further agreement in writing to that effect. The Company may terminate this agreement for any reason prior to the expiry of this agreement with 30-day notice and full vesting of stock or stock options for the period of engagement. The consultant may end this agreement with 30 days written notice prior to the end of the term. On September 21, 2020, the Company issued 50,000 shares of restricted common stock. (j) On July 23, 2020, the Company entered onto a consulting agreement with Joseph D. Kowal as an advisor to the Board of Directors of the Company. Pursuant to the agreement, the consultant is to provide among other matters, general advisory services, strategic planning and financial planning services. The consultant is to receive a monthly fee of $6,000 and to be issued 500,000 shares of restricted common stock. The shares are to be issued in quarterly installments of 125,000 beginning on the effective date and every 90 days thereafter. The initial 125,000 shares were issued on September 21, 2020. Pursuant to the terms of the agreement, the Company terminated the agreement on October 21, 2020. As of the termination date, there are no additional shares due to the Consultant. (k) On July 23, 2020, the Company entered onto a consulting agreement with Ralph Olson as an advisor to the Board of Directors of the Company. Pursuant to the agreement, the consultant is to provide among other matters, general advisory services, strategic planning and financial planning services. The consultant is to receive a monthly fee of $6,000 and to be issued 500,000 shares of restricted common stock. The shares are to be issued in quarterly installments of 125,000 beginning on the effective date and every 90 days thereafter. The initial 125,000 shares were issued on September 21, 2020. Pursuant to the terms of the agreement, the Company terminated the agreement on October 21, 2020. As of the termination date, there are no additional shares due to the consultant. (l) Effective August 1, 2020, the Company entered into an employment agreement with Dr. Levan Darjania, PhD as the Company’s Chief Science Officer. Dr. Darjania is a seasoned and accomplished research and development (“R&D”) professional and program manager with over 26-years’ experience in biotechnology, pharmaceutical drug development (both industry and academia) and proven track record of success in developing and directing in-house and collaborative R&D programs, and forward-thinking strategic planning capabilities. Pursuant to the agreement the Company has agreed to compensate Dr. Darjania an annual base salary of $250,000, and the issuance of 200,000 shares of common stock, of which 100,000 vested on the effective date and 100,000 vested six (6) months from the effective date. The initial 100,000 shares were issued on September 21, 2020. (m) On August 18, 2020, the Company entered into a one-year consulting agreement with a non-related third party. Pursuant to the terms of the agreement; the consultant will provide assistance in the Company’s public reporting responsibilities and other matters as may be requested by the Board of Directors of the Company. The Company has agreed to compensate the consultant $5,000 per month and after ninety (90) days issue the consultant $75,000 of restricted common stock, based on the market price of the common stock on that date. On November 15, 2020, the Company issued 125,000 shares of restricted common stock to the consultant, based on the price of $0.60 per share. (n) On September 1, 2020, the Company entered into a one- year consulting agreement with a consultant to provide advice on real-estate acquisitions. On September 21, 2020, pursuant to the terms of the agreement, the Company issued 50,000 shares of restricted common stock to the consultant. (o) On September 13, 2020, the Company entered into an Equity Financing Agreement (the “Financing Agreement”) with GHS Investments, LLC (“GHS”) for an equity line. Although the Company is not required to sell shares under the Financing Agreement, the Financing Agreement gives the Company the option to sell to GHS up to $25,000,000 worth of our common stock, in increments, over the period ending on the earlier of (i) the date GHS has purchased an aggregate of $25,000,000 of the Company’s common stock pursuant to the Financing Agreement, or (ii) the date that the registration statement for the registration of the secondary offering and resale of the shares to be acquired by GHS pursuant to the Financing Agreement is no longer in effect (the “Open Period”). Concurrently with the execution of the Financing Agreement, on September 13, 2020, the Company issued to GHS 150,857 restricted shares of its Common stock (“Commitment Shares”) to offset transaction costs. The Commitment Shares are deemed earned upon the execution of the Financing Agreement. The Company will sell shares of its common stock to GHS at a price equal to 100% of the lowest closing price of the Company’s common stock during the ten (10) consecutive trading day period ending on the date on which it delivers a put notice to GHS (the “Market Price”), and the Company will be obligated to simultaneously deliver the number of shares equal to120% of the put notice amount based on the Market Price. In addition, the Financing Agreement (i) imposes an ownership limitation on GHS of 4.99% (i.e., GHS has no obligation to purchase shares if it beneficially owns more than 4.99% of our common stock), (ii) requires a minimum of ten (10) trading days between put notices, and (iii) prohibits any single Put Amount from exceeding $500,000. Concurrently therewith, the Company entered into a registration rights agreement with GHS, pursuant to which the Company agreed to file a registration statement with the SEC for the registration of the secondary offering and resale of the shares to be acquired by GHS pursuant to the Financing Agreement and the 150,857 Commitment Shares and to have the registration statement declared effective by the SEC at the earliest possible date. The registration statement was declared effective by the SEC on September 21, 2020. (p) On September 18, 2020, the Company entered into a Placement Agent and Advisory Services Agreement (the “Placement Agreement”) with Boustead Securities, LLC (“BSL”), an investment banking firm that advises clients on mergers and acquisitions, capital raises, and restructuring assignments in a wide array of industries and circumstances. The initial term of this agreement shall be exclusive for six (6) months from the Company’s delivery of an offering memorandum to BSL. After the initial term, the term of the Placement Agreement will automatically be extended for additional successive one (1) year periods unless either party provides written notice to the other party of its intent not to so extend the term at least thirty (30) days before the expiration of the then current term. Under the terms of the Placement Agreement, the Company issued to BSL an advisory fee of two hundred fifty thousand (250,000) shares of restricted common stock on September 21, 2020. (q) On December 1, 2020, the Company entered onto a consulting agreement with Heidi Thomassen. Pursuant to the agreement, the consultant is to fulfill the role of Chief Communications Officer (the “CCO”) of the Company. The Company agreed to compensate the consultant $5,000 per month and issue 100,000 shares of restricted common stock annually. Each year, the first 50,000 shares are to be issued on the effective date and subsequent anniversary dates and an additional 50,000 shares are to be issued six (6) months thereafter. The Company issued the initial 50,000 shares of restricted common stock on the effective date. (r) On January 15, 2021, the Company entered into a consulting agreement with a non-related third party (the “Consultant”). Pursuant to the terms of the agreement; the Consultant, among other matters, will provide services to the Company related to reviewing, analyzing and assessing the Company’s financial requirements. The Company has agreed to compensate the Consultant 200,000 shares of restricted common stock. The first 100,000 shares were issued on the effective date and the remaining 100,000 shares are to be issued at the beginning of the third month from the effective date.

Sales concentration

Sales concentration	6 Months Ended
	Jan. 31, 2022
Sales concentration
Sales Concentration	10. Sales concentration For the three and six months ended January 31, 2022, the company recognized $41,950 in product sales. For the three and six months ended January 31, 2020, 100% of our revenue of $21,185 and $25,685, respectively, is from the land use rental income from SDGE (see Note 2). SDGE vacated the property in October 2020.

Contingent liabilities

Contingent liabilities	6 Months Ended
	Jan. 31, 2022
Sales concentration
Contingent Liabilities	11. Contingent liabilities As of January 31, 2022, the Company incurred to two separate claims against the company. The Company is early in the analysis of these claims. The Company will defend its position regarding these claims; however, the company has reserved approximately $187,000 to date. On February 15, 2022, former employee, commenced a lawsuit against the Company in Superior Court of California, County of San Diego. In this action, former employee brings claims for unpaid wages of $24,038, unused vacation pay $9,615, vested stock options of $378,000, penalties of $28,846 and fees and costs. The Company believes the allegations of the complaint are without merit and intends to defend the case vigorously. Former employee resigned from his position July 4, 2021, in an email to the Company and there weren't ever discussions around vested stock options. On December 16, 2021, Boustead Securities, LLC filed a claim against the Company in the United States District Court, Central District of California. In this action, Boustead brings claims for breach of contract. Boustead is an investment banking firm that advises on mergers and acquisitions and capital raise and, charges fees for Placement and Advisor Services. In this action Boustead claims fees for; the Companies acquisition of; Coastal Labs and Bohemian Beverage Co., both of which did not occur, Admay LLC which is a conditional contract, Castillo Seed Company for a fee of $4,800, and Primordia LLC FOR $34,491. Boustead did not originate nor had involvement in any of these transactions. Further, Boustead claims fees for the PPP Loan the Company, a Shareholder Loan to the Company from a Company owned by the CEO, and a Bridge Loan. Boustead did not originate nor had involvement in any of these transactions. Further, Boustead claims 250,000 common shares in the Company, yet the shares were already issued over a year ago and were at that time included in the total of number of outstanding shares issued. The Company believes the allegations of the complaint are without merit and intends to defend the case vigorously.

Subsequent Events

Subsequent Events	6 Months Ended
	Jan. 31, 2022
Subsequent Events
Subsequent Events	12. Subsequent Events The company did not have any subsequent events to report for the period ended January 31, 2022.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	6 Months Ended
	Jan. 31, 2022
Significant Accounting Policies
Basis Of Presentation	These financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States and are expressed in U.S. dollars. Certain amounts from the July 31, 2021 annual report may have been reclassified to conform to the presentation used in the current period.
Principles Of Consolidation	These financial statements include the accounts of the Company and its subsidiaries. Subsidiaries are all entities (including structured entities) which the Company controls. For accounting purposes, control is established by an investor when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. All inter-company balances and transactions are eliminated.
Use Of Estimates	The preparation of financial statements in accordance with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses in the reporting 21 allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.
Cash And Cash Equivalents	The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance and trust funds to be cash equivalents.
Inventory	Inventory is carried at the lower of cost or net realizable value, with the cost being determined on a first-in, first-out (FIFO) basis. The Company periodically reviews physical inventory and will record a reserve for excess and/or obsolete inventory if necessary. In July 2020, the Company planted its first large scale hemp crops for cultivation. The planting covers approximately 120 acres of land and three greenhouses. During the six months ended January 31, 2021, the Company purchased additional seeds and nutrients to plant in its greenhouses to be later transferred into the fields. The Company determined to recognize these costs as inventory as of January 31, 2021. These costs included approximately $61,000 for seeds and nutrients and $448,000 on labor to prepare the fields, plant seeds, and to begin harvesting. The Company anticipates harvesting and beginning to market and sell these crops during the fiscal year ending July 31, 2021. During the six months ended January 31,2022, the Company again recognized similar costs as inventory for the same period of 2021. These costs included approximately $267,901 in nutrients and labor to prepare the fields, plant seeds, and to begin harvesting. The Company anticipates harvesting these crops during the fiscal year ending July 31, 2022
Impairment Of Long-lived Assets	The Company evaluates the recoverability of its fixed assets and other assets in accordance with ASC 360-10-15, Impairment or Disposal of Long-Lived Assets
Related Party Transactions	The Company follows ASC 850, Related Party Disclosures
Income Taxes	The Company accounts for income taxes using the asset and liability method in accordance with ASC 740, “Income Taxes”. The asset and liability method provides that deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company records a valuation allowance to reduce deferred tax assets to the amount that is believed more likely than not to be realized.
Foreign Currency Translation	The Company’s functional and reporting currency is the U.S. dollar. Transactions in foreign currencies are translated into the currency of measurement at the exchange rates in effect on the transaction date. Monetary balance sheet items expressed in foreign currencies are translated into U.S. dollars at the exchange rates in effect at the balance sheet date. The resulting exchange gains and losses are recognized in the statement of operations.
Financial Instruments And Fair Value Measures	ASC 820, “Fair Value Measurements and Disclosures”, requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value: Level 1 Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets, quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets), or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. Level 3 Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The Company’s financial instruments consist principally of cash, accounts payable and accrued liabilities, loans payable, and amounts due to related parties. Pursuant to ASC 820, the fair value of cash is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. The recorded values of all other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations.
Stock-based Compensation	The Company records stock-based compensation in accordance with ASC 718, “Compensation – Stock Compensation” and ASC 505, “Equity Based Payments to Non-Employees”, using the fair value method. All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.
Revenue And Deferred Revenue	For the six months ended January 31,2022, the company recognized revenue from the sales of product for $49,150 and $ 21,185 in rental income from property. We recognized $40,954 in rental income for the six months ended January 31, 2021, from license fees pursuant to a license agreement for the right to use the premises at the Potrero Ranch Property for temporary storage of construction equipment. The tenant vacated the property in October 2020. The Company plans to continue to seek other additional similar license agreements or sub-leases of our properties.
Leases	The Company evaluates lease assets and lease liabilities, (if any), pursuant to ASC 842, by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing transactions. As of the date of this report, the Company has no material transactions to report.
Loss Per Share	The Company computes earnings (loss) per share in accordance with ASC 260, “Earnings per Share”. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement. Basic EPS is computed by dividing earnings (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. As of January 31, 2021, the Company does not have any potentially dilutive shares.
Comprehensive Loss	ASC 220, “Comprehensive Income”, establishes standards for the reporting and display of comprehensive loss and its components in the financial statements.
Recent Accounting Pronouncements	In July 2018, the FASB issued ASU No. 2018-10, Codification Improvements to Topic 842, Leases. The amendments in ASU 2018-10 provide additional clarification and implementation guidance on certain aspects of the previously issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”) and have the same effective and transition requirements as ASU 2016-02. Upon the effective date, ASU 2018-10 will supersede the current lease guidance in ASC Topic 840, Leases. Under the new guidance, lessees will be required to recognize for all leases, with the exception of short-term leases, a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis. Concurrently, lessees will be required to recognize a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. ASU 2018-10 is effective for private companies and emerging growth public companies for interim and annual reporting periods beginning after December 15, 2019, with early adoption permitted. The guidance is required to be applied using a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative periods presented in the financial statements. During the three and six months ended January 31, 2021, the Company assessed the impact this guidance had on its financial statements and concluded that at present ASU No. 2018-10 has no impact on its financial statements.

Fixed assets (Tables)

Fixed assets (Tables)	6 Months Ended
	Jan. 31, 2022
Fixed assets (Tables)
Schedule Of Fixed Assets	Useful Life Balance at July 31, 2021 Additions (deletions) Accumulated Depreciation Balance at January 31, 2022 Production equipment 5 years $ 854,899 $ (102,177 ) $ (68,303 ) $ 684,419 Furniture and office equipment 5 years 4,859 - (817 ) 4,042 Buildings and improvements 15 years 450,206 - (16,366 ) 433,840 Land 4,212,362 - - 4,212,362 $ 5,522,326 $ (102,177 ) $ (85,486 ) $ 5,334,663

Loans Payable (Tables)

Loans Payable (Tables)	6 Months Ended
	Jan. 31, 2022
Loans Payable
Schedule Of Outstanding Notes Payable	January 31, 2022 July 31, 2021 Secured Promissory Note payable, interest at 15%, matures August 15, 2024. 1,760,000 1,760,000 Secured Promissory Note payable, interest at 6%, matures August 23, 2024 2,750,000 2,750,000 Promissory Note, interest at 5.66%, matures October 1, 2023 85,331 112,012 Paycheck Protection Program loan 444,850 444,850 Golden State note payable 55,000 - Secured Promissory Note payable, interest at 15%, matures June 15, 2022, net of discount 2,668,748 2,660,186 Promissory Note/ interest at 4.75, matures March 2,2022 406,138 406,137 Sub- total notes payable, net of discount 8,170,067 8,133,185 Less long-term portion 4,547,465 7,235,766 Current portion of notes payable $ 3,622,602 $ 897,409

Related Party Transactions (Tab

Related Party Transactions (Tables)	6 Months Ended
	Jan. 31, 2022
Related Party Transactions
Schedule Of Reimbursements Received	Balance July 31, 2021 $ 3,128,463 Advances 422,421 Reimbursements (77,913 ) Balance January 31, 2022 $ 3,472,971
Schedule Of Expenses And Payments	Balance at July 31, 2021 Additions Payments Balance at January 31, 2022 CEO, parent $ 180,000 $ 277,650 $ - $ 457,650 Chief Technology Officer (7,500 ) 7,500 5,000 (5,000 ) Chief Operating Officer 113,679 22,500 28,500 107,679 Chief Financial Officer - 22,500 8,250 14,250 Chief Communication Officer - 27,597 10,000 17,597 Chief Project Manager 40,468 22,750 7,500 55,718 Former CEO, subsidiary 67,500 - - 67,500 Former President, subsidiary 67,500 - - 67,500 Former Chief Agricultural Officer, subsidiary 27,144 - - 27,144 Former Director 35,000 - - 35,000 $ 523,791 $ 380,497 $ 59,250 $ 845,038

Nature of Operations and Cont_2

Nature of Operations and Continuance of Business (Details Narrative) - USD ($)	6 Months Ended
	Jan. 31, 2022	Jul. 31, 2021	Jan. 31, 2021
Accumulated Deficit	$ (60,452,942)	$ (58,885,730)
Cultivation and branding enterprise [Member]
Description, Ordinary Agricultural Commodity	The Company is an innovative, full-scope, science-driven, premium hemp cultivation and branding enterprise focused on the cultivation and processing of industrial hemp for cannabidiol (“CBD”). The Hemp Farming Act of 2018 removed hemp from Schedule I controlled substances (defined as cannabis with less than 0.3% THC), making it an ordinary agricultural commodity.
Accumulated Deficit			$ (60,452,942)
Working Capital Deficit			$ (9,065,108)

Significant Accounting Polici_3

Significant Accounting Policies (Details Narrative) - USD ($)	6 Months Ended
	Jan. 31, 2022	Jan. 31, 2021
Significant Accounting Policies
Cost Of Seeds And Nutrients		$ 61,000
Revenue Recognized	$ 49,150
Similar Inventory Cost	267,901
Rental Income	$ 21,185	40,954
Labor Cost		$ 448,000

Fixed Assets (Details)

Fixed Assets (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jan. 31, 2022	Jul. 31, 2021
Production Equipment	$ 684,419	$ 854,899
Furniture And Office Equipment	4,042	4,859
Buildings And Improvements	433,840	450,206
Land	4,212,362	4,212,362
Purchase Of Fixed Assets	$ 5,334,663	$ 5,522,326
Useful Life [Member]
Production Equipment	5 years
Furniture And Office Equipment, Useful Life	5 years
Buildings And Improvements	15 years
Additions [Member]
Furniture And Office Equipment	$ 0
Buildings And Improvements	0
Land	0
Production Equipment	(102,177)
Purchase Of Fixed Assets	(102,177)
Accumulated Depreciation [Member]
Furniture And Office Equipment	(817)
Production Equipment	(68,303)
Buildings And Improvements	(16,366)
Land	0
Purchase Of Fixed Assets	$ (85,486)

Fixed Assets (Details Narrative

Fixed Assets (Details Narrative) - USD ($)	6 Months Ended
	Jan. 31, 2022	Jan. 31, 2021
Fixed Assets (Details Narrative)
Depreciation Expenses	$ 137,686	$ 63,465

Revenue and deferred revenue (D

Revenue and deferred revenue (Details Narrative) - USD ($)	6 Months Ended
	Jan. 31, 2022	Jan. 31, 2021
Revenue and deferred revenue
Rental Income	$ 21,185	$ 40,954
Revenue, Sales Of Product	$ 49,150

Loans Payable (Details)

Loans Payable (Details) - USD ($)	Jan. 31, 2022	Jul. 31, 2021
Promissiory Note One [Member]
Notes Payable	$ 85,331	$ 112,012
Promissiory Note Two [Member]
Notes Payable	406,138	406,137
Secured Promissory Note Payable [Member]
Notes Payable	1,760,000	1,760,000
Secured Promissory Note Payable One [Member]
Notes Payable	2,750,000	2,750,000
Paycheck Protection Program Loan [Member]
Notes Payable	444,850	444,850
Secured Promissory Note Payable Two [Member]
Notes Payable	2,668,748	2,660,186
Golden State note payable [Member]
Notes Payable	55,000	0
Notes Payable Outstanding [Member]
Notes Payable	8,170,067	8,133,185
Less Long-term Portion	4,547,465	7,235,766
Current Portion Of Notes Payable	$ 3,622,602	$ 897,409

Loans Payable (Details Narrativ

Loans Payable (Details Narrative) - USD ($)	Dec. 15, 2020	Aug. 15, 2019	Apr. 30, 2020	Aug. 23, 2019	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2022	Jan. 31, 2021	Jul. 31, 2021	Sep. 12, 2019
Current Liabilities					$ 9,334,343		$ 9,334,343		$ 8,322,776
Interest Expense					$ 303,685	$ 210,363	600,922	$ 401,803
Debt Discount							8,563	$ 734
Secured Promissory Note One [Member]
Notes Payable	$ 2,668,748			$ 2,750,000
Interest Rate	15.00%			6.00%
Maturity Date	Jun. 15, 2022			Aug. 23, 2024
Unamortized Debt Discount	$ 0
Interest Expense							100,078
Debt Discount	$ 26,423
Repayment Of Related Party Debt							1,140,000
Secured Promissory Note One [Member] | Maximum [Member]
Interest Expense							$ 200,156
Secured Promissory Note [Member]
Notes Payable		$ 1,760,000
Interest Rate		15.00%
Maturity Date		Aug. 15, 2024
Paycheck Protection Program [Member]
Notes Payable										$ 183,031
Proceeds From Issuance Of Debt			$ 444,850
Interest Rate			1.00%		5.66%		5.66%
Description, Of Loan Provided			provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business
Monthly Payments							$ 4,290
Maturity Period							48 years
Current Liabilities					$ 47,866		$ 47,866
Long-term Liabilities					$ 37,465		$ 37,465

Convertible Note Payable (Detai

Convertible Note Payable (Details Narrative) - USD ($)	Jan. 08, 2020	Aug. 19, 2020	Mar. 31, 2020	Feb. 20, 2020	Dec. 31, 2019	Jul. 31, 2020
Note Balance		$ 0
Principal Amount		$ 200,000
Paycheck Protection Program [Member]
Principal Amount			$ 500,000			$ 171,213
Purchase Price	$ 600,000
Discounted Convertible Promissory Note	$ 750,000
Share Price	$ 2.50
Conversion Price	$ 2.50
Common Stock Purchase Warrant	250,000
Interest Rate	10.00%
Common Stock, Exercise Price	$ 3
Amendment Description	Note is initially convertible at a price per share equal to $2.50 (the “Fixed Conversion Price”); provided, however, that during the continuance of an event of default under the Note, the conversion price shall be equal to 75% of the lowest trading price of the Company’s common stock during the 30 trading days prior to conversion.		the maturity date of the Note was extended to August 20, 2020, (iii) the conversion price of the Note was established as 75% of the lowest trading price of our common stock during the 30 trading days prior to conversion
Initial Purchase Price					$ 100,000
Proceeds From Debt					85,000
Fees					$ 15,000
Original Issue Discount				$ 150,000
Paid The Purchase Price				$ 500,000
Payment Of Debt			$ 250,000

Related Party Transactions (Det

Related Party Transactions (Details) - Alita [Member]	6 Months Ended
	Jan. 31, 2022USD ($)
Due To Related Party Debt, Beginning Balance	$ 3,128,463
Advances And Interest Charged	422,421
Reimbursements	(77,913)
Due To Related Party Debt, Ending Balance	$ 3,472,971

Related Party Transactions (D_2

Related Party Transactions (Details 1)	6 Months Ended
	Jan. 31, 2022USD ($)
Payment Of Related Party Expenses Beginning	$ 523,791
Additions	380,497
Payments	59,250
Payment Of Related Party Expenses Ending	845,038
Former Director [Member]
Payment Of Related Party Expenses Beginning	35,000
Additions	0
Payments	0
Payment Of Related Party Expenses Ending	35,000
Former President, Subsidiary [Member]
Payment Of Related Party Expenses Beginning	67,500
Additions	0
Payments	0
Payment Of Related Party Expenses Ending	67,500
Chief Operating Officer [Member]
Payment Of Related Party Expenses Beginning	113,679
Additions	22,500
Payments	28,500
Payment Of Related Party Expenses Ending	107,679
Chief Project Manager [Member]
Payment Of Related Party Expenses Beginning	40,468
Additions	22,750
Payments	7,500
Payment Of Related Party Expenses Ending	55,718
Former Chief Agricultural Officer, Subsidiary [Member]
Payment Of Related Party Expenses Beginning	27,144
Additions	0
Payments	0
Payment Of Related Party Expenses Ending	27,144
Former CEO, Subsidiary [Member]
Payment Of Related Party Expenses Beginning	67,500
Additions	0
Payments	0
Payment Of Related Party Expenses Ending	67,500
Chief Technology Officer [Member]
Payment Of Related Party Expenses Beginning	(7,500)
Additions	7,500
Payments	5,000
Payment Of Related Party Expenses Ending	(5,000)
Chief Financial Officer [Member]
Payment Of Related Party Expenses Beginning	0
Additions	22,500
Payments	8,250
Payment Of Related Party Expenses Ending	14,250
Chief Communication Officer [Member]
Payment Of Related Party Expenses Beginning	0
Additions	27,597
Payments	10,000
Payment Of Related Party Expenses Ending	17,597
CEO, Parent [Member]
Payment Of Related Party Expenses Beginning	180,000
Additions	277,650
Payments	0
Payment Of Related Party Expenses Ending	$ 457,650

Related Party Transactions (D_3

Related Party Transactions (Details Narrative) - USD ($)	1 Months Ended	6 Months Ended
	Sep. 21, 2020	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Imputed Interest			$ 167,831	$ 114,985
Common Stock Shares Issued, Value		$ 0	$ 1,500
Alita [Member]
Issued And Outstanding Common Stock		49.80%
Chief Project Manager [Member]
Shares Issued Upon Exchange Of Production Equipment	50,000
Common Stock Shares Issued, Value	$ 51,500

Share Issuances (Details Narrat

Share Issuances (Details Narrative) - USD ($)	Sep. 13, 2020	Sep. 02, 2020	Nov. 15, 2020	Sep. 29, 2020	Sep. 21, 2020	Jan. 31, 2022
CFO of the Company [Member]
Common Stock Shares Issued To Related Party, Shares					50,000
Common Stock Shares Issued To Related Party, Amount					$ 60,750
Non related third party [Member]
Common Stock Shares Issued To Related Party, Shares				140,000
Common Stock Shares Issued To Related Party, Amount				$ 137,200
Consulting Agreement [Member]
Common Stock Shares Issued To Related Party, Shares					200,000
Common Stock Shares Issued To Related Party, Amount					$ 92,000
Consulting Agreement [Member] | January 15, 2021 [Member]
Common Stock Shares Issued To Related Party, Shares						100,000
Common Stock Shares Issued To Related Party, Amount						$ 75,000
Consulting Agreement [Member] | December 1, 2020 [Member]
Common Stock Shares Issued To Related Party, Shares						50,000
Common Stock Shares Issued To Related Party, Amount						$ 34,000
Chief Project Manager [Member]
Common Stock Shares Issued To Related Party, Shares					100,000
Common Stock Shares Issued To Related Party, Amount					$ 148,000
SRAX [Member]
Shares Issued In Exchage For Right To Use Assets, Shares		500,000
Shares Issued In Exchage For Right To Use Assets, Amount		$ 355,550
Financing agreement with GHS [Member]
Common Stock Shares Issued To Related Party, Shares	150,857
Common Stock Shares Issued To Related Party, Amount	$ 155,383
CEO [Member]
Common Stock Shares Issued To Related Party, Shares					250,000
Common Stock Shares Issued To Related Party, Amount					$ 370,000
CPM [Member] | Stock Purchase Agreement [Member]
Common Stock Shares Issued To Related Party, Shares					50,000
Common Stock Shares Issued To Related Party, Amount					$ 51,500
Chief Science Officer [Member]
Common Stock Shares Issued To Related Party, Shares					100,000
Common Stock Shares Issued To Related Party, Amount					$ 87,250
Assistant Agricultural Operations Manager [Member]
Common Stock Shares Issued To Related Party, Shares					25,000
Common Stock Shares Issued To Related Party, Amount					$ 37,000
Placement agreement with BSL [Member]
Common Stock Shares Issued To Related Party, Shares					250,000
Common Stock Shares Issued To Related Party, Amount					$ 187,500
Consultants 2 [Member]
Common Stock Shares Issued To Related Party, Shares					125,000
Common Stock Shares Issued To Related Party, Amount					$ 113,750
Consultants 1 [Member]
Common Stock Shares Issued To Related Party, Shares			125,000		125,000
Common Stock Shares Issued To Related Party, Amount			$ 75,000		$ 113,750
Consultants [Member]
Common Stock Shares Issued To Related Party, Shares			100,000		50,000
Common Stock Shares Issued To Related Party, Amount			$ 200,000		$ 58,500
Consultants 3 [Member]
Common Stock Shares Issued To Related Party, Shares					100,000
Common Stock Shares Issued To Related Party, Amount					$ 187,000
Shareholder [Member]
Common Stock Shares Issued To Related Party, Shares					125,000
Common Stock Shares Issued To Related Party, Amount					$ 185,000

Commitments Contigencies (Detai

Commitments Contigencies (Details Narrative) - USD ($)	Jan. 15, 2021	Sep. 13, 2020	Oct. 31, 2021	Jan. 31, 2021	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020	Nov. 15, 2020	Sep. 21, 2020
Stock-based Compensation Expense					$ 0	$ 2,288,050
Common Stock Shares Value			$ 0
Consulting Agreement [Member]
Restricted Shares Issued	200,000
Restricted Shares Issued Description	The first 100,000 shares were issued on the effective date and the remaining 100,000 shares are to be issued at the beginning of the third month from the effective date.
August 1, 2019 [Member] | Consulting Agreement [Member]
Restricted Shares Issued					125,000
September 1, 2018 [Member] | Consulting Agreement [Member]
Consulting Fee Per Month					$ 2,500
Consulting Agreement Description					The agreement can be extended to four years upon mutual agreement. Upon completion of a minimum $1,000,000 financing, the Company will increase this payment to $5,000 per month. Upon completion of a minimum $5,000,000 financing or profitable operations
Frequency Of Periodic Payments					Monthly
September 1, 2020 [Member] | Consulting Agreement [Member]
Restricted Shares Issued									50,000
August 18, 2020 [Member] | Non related third party [Member]
Restricted Shares Issued								125,000
Consulting Fee Per Month					$ 5,000
Restricted Shares Issued Amount					$ 75,000
Price Per Share								$ 0.60
February 1, 2020 [Member] | Consulting Agreement [Member]
Restricted Shares Issued					100,000
CEO [Member] | August 1, 2019 [Member]
Stock-based Compensation Expense				$ 22,500			$ 45,000
Restricted Shares Issued					250,000
Common Stock Issued					250,000
Additional Shares Issued					250,000
Consulting Fee Per Month					$ 7,500
Assistant Agricultural Operations Manager [Member] | August 1, 2019 [Member]
Restricted Shares Issued					25,000
Common Stock Issued					25,000
Consulting Fee Per Month					$ 2,000
Signing Bonus					$ 4,000
Heidi Thomassen [Member] | December 1, 2020 [Member] | Consulting Agreement [Member]
Restricted Shares Issued					100,000
Consulting Fee Per Month					$ 5,000
Restricted Shares Issued Description					The Company agreed to compensate the consultant $5,000 per month and issue 100,000 shares of restricted common stock annually.
GHS Investments LLC [Member] | Financing Agreement [Member]
Restricted Shares Issued		150,857
Purchased Aggregate Fair Value		$ 25,000,000
Common Stock Restricted Shares		150,857
Commitment Shares		150,857
Common Stock Shares Value		$ 25,000,000
Closing Price Description		The Company will sell shares of its common stock to GHS at a price equal to 100% of the lowest closing price of the Company’s common stock during the ten (10) consecutive trading day period ending on the date on which it delivers a put notice to GHS (the “Market Price”), and the Company will be obligated to simultaneously deliver the number of shares equal to120% of the put notice amount based on the Market Price. In addition, the Financing Agreement (i) imposes an ownership limitation on GHS of 4.99% (i.e., GHS has no obligation to purchase shares if it beneficially owns more than 4.99% of our common stock), (ii) requires a minimum of ten (10) trading days between put notices, and (iii) prohibits any single Put Amount from exceeding $500,000.
Exceeding Amount		$ 500,000
Consultant [Member] | December 1, 2020 [Member]
Restricted Shares Issued					50,000
Boustead Securities LLC [Member] | September 18, 2020 [Member]
Restricted Shares Issued									250,000
Restricted Value					$ 187,500
Todd Mueller [Member] | February 13, 2020 [Member] | Consulting Agreement [Member]
Restricted Shares Issued									50,000
Consulting Agreement Description					the Company agreed to pay a consulting fee of 100,000 shares, 50,000 shares would be delivered upon the execution of the agreement (certificated on July 14, 2020) and 50,000 delivered in six months based on the continuation of the agreement.
Share Issued For Services					100,000
Shares Issued In First Installment					50,000
Shares Issued In Second Installment					50,000
Chief Project Manager [Member] | August 1, 2019 [Member]
Restricted Shares Issued					100,000
Common Stock Issued					200,000
Consulting Fee Per Month					$ 7,500
Maturity Period					5 years
Agreement To Pay Bonus					$ 15,000
Kyle MacKinnon [Member] | November 15, 2019 [Member]
Restricted Shares Issued					200,000			100,000
Consulting Fee Per Month					$ 7,500
Shares Description					Each year, the first 100,000 shares are to be issued on the effective date and subsequent anniversary dates and an additional 100,000 shares are to be issued six (6) months thereafter.
Ralph Olson [Member] | July 23, 2020 [Member]
Consulting Fee Per Month					$ 6,000
Consulting Agreement Description					The shares are to be issued in quarterly installments of 125,000 beginning on the effective date and every 90 days thereafter. The initial 125,000 shares were issued on September 21, 2020. Pursuant to the terms of the agreement, the Company terminated the agreement on October 21, 2020.
Restricted Shares To Be Issued					500,000
Joseph D. Kowal [Member] | July 23, 2020 [Member]
Consulting Fee Per Month					$ 6,000
Consulting Agreement Description					The shares are to be issued in quarterly installments of 125,000 beginning on the effective date and every 90 days thereafter. The initial 125,000 shares were issued on September 21, 2020. Pursuant to the terms of the agreement, the Company terminated the agreement on October 21, 2020.
Restricted Shares To Be Issued					500,000
Independent Director [Member] | November 15, 2019 [Member]
Common Stock Issued					100,000
Stock Issuable					50,000
Stock Payable Value					$ 100,000
Dr. Darjania [Member] | August 1, 2020 [Member] | Employment Agreement [Member]
Shares Description					the issuance of 200,000 shares of common stock, of which 100,000 vested on the effective date and 100,000 vested six (6) months from the effective date.
Annual Base Salary					$ 250,000
Common Stock Shares Issuable Upon Exercise Of Options					200,000
Common Stock Shares Vested					100,000

Sales Concentration (Details Na

Sales Concentration (Details Narrative) - USD ($)	3 Months Ended			6 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Revenue				$ 41,950
Revenue	$ 63,135	$ 0		$ 67,635	$ 40,954
Financing Agreement [Member] | San Diego Gas and Electric [Member]
Revenue			$ 21,185			$ 25,685
Rental Income Land Use						100.00%

Contingent liabilities (Details

Contingent liabilities (Details Narrative) - USD ($)	1 Months Ended	6 Months Ended
	Feb. 15, 2022	Jan. 31, 2022
Wages Unpaid	$ 24,038
Unused Pay, Vacation	9,615
Stock Options, Vested	378,000
Penalties,fees And Cost	28,846
Reserved Amount		$ 187,000
Consultants 1 [Member]
Contract Fee	34,491
Consultants [Member]
Contract Fee	$ 4,800
Common Shares Issued	250,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Mar. 02, 2021	Feb. 15, 2021	Mar. 02, 2022	Feb. 01, 2021
Subsequent Events
Agent Services		$ 100,000,000
Asset Purchase Price	$ 431,137
Cash Payment	25,000
Restricted Common Stock				$ 325,000
Promissory Note	$ 406,137
Note Matures			4.75%